Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042963 (vomiting)
 31,883 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

New labelling processes installed without adequate ventilation control in an electric motor factory exposed production line workers to toxic gases. Symptoms of eye and respiratory tract irritation together with complaints of headache, fever, chills, dizziness, malaise, general weakness, nausea, and vomiting were widespread. Chest signs, radiographic abnormalities, reduction in ventilatory function, and blood gas abnormalities were found in some cases. Epidemiological analysis of the spatial and temporal distribution of cases supported an exposure effect relationship. Investigations suggested ozone and possibly phosgene and associated trichloroacetyl chlorides as the toxic agents that were generated by an ultraviolet print curing arrangement and perchloroethylene used as a cleaning solvent.
 ...
PMID:An outbreak of illness after occupational exposure to ozone and acid chlorides. 404 87

(PGF2alpha) Prostaglandin F2alpha was administered intraamniotically to 16 patients in 3 groups: molar pregnancy (8 cases), fetal death (6 cases), and anencephalic fetus (2 cases). These particular types of situations were selected because the effects of PGs upon the product were unknown. PG was administered in dosages between 3 and 200 mcg after being prepared in an ethanol solution. It appeared to have no effect on uterine contractility. It is best to start contractility stimulation with low doses which should be increased progressively according to uterine response. Tone, intensity, frequency, and uterine activity increased when PG dose was increased. Uterine labor as to maturity and cervical dilatation, was studied in the 3 groups. Blood pressure was registered in 2 patients with molar pregnancy; there were no changes during the 1st hours of the study. However, during the last part, differential pressure increased by systolic increase. In 4 patients with fetal death, cervical dilatation register was taken. Average dilatation time (going from 2-10 cm) was 9.50 hours. There were such side effects as slight nausea, vomiting, and chills. 1 of the patients presented with hypotension upon administration of PGF2alpha 200 mcg. 4 patients suffered complications; 1 with molar pregnancy had a possible pulmonary embolism by trophoblast, another had hemorrhage and hypotension, 1 patient with fetal death had immediate hypotension after administration of 200 mcg, and the other had deciduo-myometritis which cleared with antibiotics and curettage. No other subjects experienced complications. Intraamniotic PG administration produced few side effects. (author's modified)
 ...
PMID:[Effect of prostaglandin F2a on the contractility of the pregnant human uterus]. 441 23

To determine the cervical relaxant properties and side effects of intravaginal administration of prostaglandin E2 (PGE2) in nonpregnant patients, 5 subjects in midluteal phase were given 20 mg of PGE2 by intravaginal suppository. In 4 patients, no change was found in the diameter of the internal cervical os 12 hours after treatment; the other patient showed an increase of 1 mm. 4 of 5 experienced prolonged nausea, 3 experienced severe vomiting, 2 had diarrhea, all 5 suffered chills, 3 had tachycardia, 4 had fevers, 4 had abdominal cramping, and 1 suffered hypotension. These side effects were severe and their potential seriousness makes this drug inappropriate for use in nonpregnant patients via this route of administration.
 ...
PMID:The cervical relaxant properties of prostaglandin E2 in non pregnant subjects. 478 16

This is a case report of a serious complication that occurred about 5 weeks after the insertion of an IUD. The patient, a 34 year old Caucasian woman, gravida 7, para 5 and abortions 2, was admitted to the hospital for chills, fever, abdominal pain, nausea, vomiting and diarrhoea which began 3 days prior to admission. Menstrual flow had begun 10 days earlier and had increased. Twenty-four hours before admission patient had become disoriented and confused. The Saf-T-Coil 33-S was removed from the uterus. Bacterial cultures were taken from the cervical canal. The uterus and adnexa were tender. There were no pelvic masses. Laboratory tests were not revealing. X-ray of the abdomen was compatible with paralytic ileus. The patient was treated for 3 days with intravenous antibiotics and other supportive measures. On the fourth day a duldo-centrisis yielded gross pus but smears and cultures showed no pathogenic organisms. A laparotomy was performed and a purulent fibrinoid exudate was found covering the uterus and adjacent intestines. No uterine perforation was present. Cultures from the cervix, bloodstream, urine and pus grew no pathogenic organisms. Other organs appeared normal. After a difficult convalescence, patient was discharged in the twenty-second day.
 ...
PMID:Severe peritonitis complicating an intrauterine contraceptive device. 556

Two hundred forty-three patients have received WR-2721 in Phase I-II studies. Separate studies were conducted in which patients with advanced malignancies received WR-2721 before single or multiple doses of radiotherapy or in single doses prior to cyclophosphamide, nitrogen mustard or cis-platinum. Single doses were escalated from 25 to 1330 mg/m2. An Acceptable Tolerated Dose (ATD) of 740 mg/m2 infused in 15 minutes has been established and is currently used in Phase II studies. Significant persistent hypotension (greater than 20 torr systolic) as a dose-limiting toxicity has occurred in 5% of patients in the single dose study. Fifty-five patients have been entered in the multiple dose trial. Dose levels of 340 mg/m2, four times a week for three weeks, and 250 mg/m2, four times a week for six weeks have been reached. There were five idiosynchratic reactions (fever, chills, rash, hypotension), one of which was severe. Some patients withdrew from the multiple dose study because of vomiting after each injection, or fear. No deaths nor any long-term untoward effects were observed. There is no suggestion of tumor protection.
 ...
PMID:Toxicity of WR-2721 administered in single and multiple doses. 609 Mar 69

An invasive strain of Escherichia coli (ONT:NM) was isolated from stool specimens from 7 of 10 ill passengers who developed diarrhea during a 5-day ocean cruise. The ill passengers had shared no common exposures off the ship before or during the cruise. Three of the persons whose stools were cultured were part of a tour group of 219 persons, and a food consumption and health history questionnaire was completed by 190 members (87%) of this tour group. Forty-seven (25%) had had diarrhea during the cruise; other symptoms among those with diarrhea included nausea (72%), abdominal cramps (68%), headache (68%), chills (60%), dizziness (53%), myalgias (43%), subjective fever (36%), and vomiting (26%). The median duration of symptoms was 3 days. Eating at cold buffets on ship and eating potato salad, a buffet food item, were significantly associated with illness. No evidence of secondary spread of illness in household contacts of the ill person was found.
 ...
PMID:Outbreak of invasive Escherichia coli gastroenteritis on a cruise ship. 637 5

We have treated 11 patients having a variety of tumor types and three patients having mitomycin-C-associated thrombotic thrombocytopenic purpura (TTP) with extracorporeal plasma perfusion through filters containing immobilized protein A from Staphylococcus aureus. In performing more than 140 procedures we observed only minimal toxicity, of which fever, chills, nausea, and vomiting were the most common symptoms, occurring in 25% of the patients. Significant decrease in blood pressure and bronchospasm were rare complications. However, none of these side effects were severe enough to require therapeutic intervention. The antitumor effect of immunoperfusion was modest. In 10 adequately treated patients there was one measurable tumor reduction (40% decrease of original tumor mass). Two patients had correction of total small bowel obstruction, with return to normal food intake and restoration of normal bowel habits, lasting for 6 and 3 months; and two of the two adequately treated TTP patients had dramatic hematological improvement after four and five immunoperfusion treatments and are well at present. We found direct correlation between extent of complement activation and clinical toxicity. By temperature manipulation of the perfusion procedure we were able to control the above-mentioned side effects caused by complement activation.
 ...
PMID:Clinical experiences with extracorporeal immunoperfusion of plasma from cancer patients. 637 16

Thalicarpine, a plant alkaloid of novel structure, was evaluated in a phase II clinical trial. Fourteen previously treated patients with advanced malignant disease were given thalicarpine at a dose of 1100 mg/m2 weekly as a constant 2-hour iv infusion. Common toxic effects included nausea, ECG changes, arm pain, and lethargy; less frequent effects included vomiting, tachycardia, hypotension, pain distant from infusion site, urticaria, chills, diarrhea, and mydriasis. There was no hematologic, hepatic, or renal toxicity. There were no complete or partial objective responses. Although the drug's true response rate in any given tumor type cannot be determined, its absence of activity in man, to date, and the recent closing of its IND, make further clinical investigation with thalicarpine unlikely.
 ...
PMID:An abbreviated phase II trial of thalicarpine. 645 Dec 89

This study was designed to evaluate the clinical tolerance to multiple IM injections of rDNA-produced human alpha-2 interferon (IFN) (Schering-Plough 30500) in patients with solid tumours. IFN was administered in escalating IM doses in separate groups of patients daily for 14 days and then twice weekly for a further 10 weeks. The dosage levels were 1, 3, 10, and 30 million U/injection. Subjective toxicity could be divided into two types, acute and chronic. The acute reactions took the form of an influenza-like syndrome consisting in chills, rigors, headache, tremor, nausea, vomiting, and myalgia. These symptoms were dose-related but tachyphylaxis developed with continued dosing. The chronic toxicity consisted of malaise, lethargy, fatigue, anorexia, and confusion. These symptoms were not so dose-dependent and tended to become more severe with prolonged treatment. Objective toxicity consisted of myelosuppression and liver dysfunction. Granulocyte counts below 1.0 X 10(9)/l were seen in three patients at the 30-million-U level, with platelet counts less than 100 X 10(9)/l in two of these. Elevation of the liver enzymes were seen in all five patients treated at 30 million U, but returned to normal after 1 week without IFN in all but one patient. A tolerable dose (IM) for phase II/III studies lies between 3 and 10 million U for daily scheduling and between 10 and 30 million U for twice-weekly injections.
 ...
PMID:A phase I toxicity study of human rDNA interferon in patients with solid tumours. 646 93

The toxicity of intravenously administered Corynebacterium parvum was observed in 14 patients with stage II melanoma and in 14 patients with advanced ovarian carcinoma. Those with melanoma were rendered disease-free by surgery prior to treatment. The ovarian cancer patients had failed chemotherapy with alkylating agents and were receiving C. parvum prior to chemotherapy as part of an immunochemotherapy trial. Both clinical and laboratory parameters were observed. The mean daily C. parvum dose for melanoma patients was 2.03 mg/m2 and for ovarian carcinoma patients 2.02 mg/m2. The most important clinical toxic effects noted were fever, chills, blood pressure changes, headache, nausea, vomiting and diaphoresis. Laboratory toxicity was mild, with small decreases in hemoglobin levels, white blood cell counts and uric acid and albumin concentrations occurring in some patients. Serum bilirubin and SGOT levels tended to rise. In addition to determining the frequency of clinical toxic effects by treatment course, consideration was also given to frequency per treatment day, correlation of the occurrence of different toxicities in the same patient, time of onset of each toxicity and, for vital signs, to intensity of change and duration. In this analysis no major differences in toxicity were observed when C. parvum was given to the two patient groups.
 ...
PMID:Corynebacterium parvum toxicity in patients with limited and advanced malignancy. 653 97


<< Previous 1 2 3 4 5 6 7 8 9 10